✦ LIBER ✦

Su1061 Pearl-IV: a 12-Week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves Svr12 Rates≥90% in Treatment-Naïve Adults Infected With Hepatitis C Virus Genotype 1A

✍ Scribed by Bernstein, David; Lalezari, Jacob; Luo, Yan; Box, Terry D.; Younes, Ziad H.; Green, Sinikka; Bhandari, Bai R.; Sepe, Thomas; Cooper, Curtis; Tam, Edward; Tsai, Naoky; Hassanein, Tarek; Xie, Wangang; Podsadecki, Thomas

Book ID: 122284087
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 544 KB
Volume: 146
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(14)63552-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P1299 PEARL-III: 12 WEEKS OF ABT-450/R/2

P1299 PEARL-III: 12 WEEKS OF ABT-450/R/267 + ABT-333 ACHIEVED SVR IN >99% OF 419 TREATMENT-NAIVE HCV GENOTYPE 1B-INFECTED ADULTS WITH OR WITHOUT RIBAVIRIN

✍ Ferenci, P.; Nyberg, A.; Enayati, P.; Bernstein, D.; Baruch, Y.; Caruntu, F.A.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 62 KB

475 SAPPHIRE I: Phase 3 Placebo-Controll

475 SAPPHIRE I: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 631 Treatment-Naïve Adults With Hepatitis C Virus Genotype 1

✍ Kowdley, Kris V.; Feld, Jordan J.; Coakley, Eoin; Sigal, Samuel; Nelson, David R 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 825 KB

929e PEARL-II: Randomized Phase 3 Trial

929e PEARL-II: Randomized Phase 3 Trial of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333 With or Without Ribavirin in Hepatitis C Virus Genotype 1b-Infected, Treatment-Experienced Patients

✍ Andreone, Pietro; Colombo, Massimo; Enejosa, Jeffrey V.; Koksal, Iftihar; Ferenc 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 50 KB

O1 SAPPHIRE II: PHASE 3 PLACEBO-CONTROLL

O1 SAPPHIRE II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1

✍ Zeuzem, S.; Jacobson, I.; Baykal, T.; Marinho, R.T.; Poordad, F.; Bourliere, M.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 152 KB

O163 TURQUOISE-II: SVR12 RATES OF 92–96%

O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV)

✍ Poordad, F.; Hezode, C.; Trinh, R.; Kowdley, K.V.; Zeuzem, S.; Agarwal, K.; Shif 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 152 KB

Tu2039 TURQUOISE-II: SVR12 Rates of 92%-

Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)

✍ Kowdley, Kris V.; Poordad, Fred; Trinh, Roger; Hezode, Christophe; Zeuzem, Stefa 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 46 KB